Zobrazeno 1 - 10
of 204
pro vyhledávání: '"Toyoaki Hida"'
Publikováno v:
Targeted Oncology. 17:597-604
Small molecule mesenchymal-epithelial transition (MET) inhibitors, such as crizotinib, capmatinib, and tepotinib, are treatment options for metastatic non-small cell lung cancer (NSCLC) in adult patients whose tumors have a mutation that leads to MET
Autor:
Yuki Katsuya, Shigehisa Kitano, Makiko Yamashita, Mayu Ouchi, Shigehiro Yagishita, Akinobu Hamada, Hiromi Nakamura, Fumie Hosoda, Tatsuhiro Shibata, Noriko Motoi, Takayuki Nakayama, Takashi Seto, Shigeki Umemura, Yukio Hosomi, Miyako Satouchi, Makoto Nishio, Toshiyuki Kozuki, Toyoaki Hida, Yuichiro Ohe, Hidehito Horinouchi
Publikováno v:
Frontiers in Oncology. 12
In a phase II trial of nivolumab in advanced thymic carcinoma (UMIN000022007), long SD (SD for more than 24 weeks) was seen in three patients and irAE (Gr2 or higher) was seen in four patients among 15 patients. Here, we report preplanned comprehensi
Autor:
Isamu Okamoto, Tatsuo Ohira, Nobuyuki Yamamoto, Hidehito Horinouchi, Toyoaki Hida, Shinji Atagi, Tatsuro Fukuhara, Miyako Satouchi, Kazuma Kishi, Shunichi Sugawara, Shi Rong Han, Hideo Saka, Victoria Ebiana, Katsuyuki Hotta, Keisuke Aoe, Kazuhiko Nakagawa, Hiroshi Sakai, Hiroaki Okamoto, Kazuo Noguchi, Kaname Nosaki, Atsushi Horiike, Shigeki Umemura, Toshiaki Takahashi, Takayasu Kurata, Nobuyuki Katakami, Akimasa Sekine
Publikováno v:
Cancer Science
Cancer Sci
Cancer Sci
This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE‐024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non‐small‐cell lung cancer without EGFR/ALK alterations and a programmed death li
Autor:
Anders Mellemgaard, Ghada F. Ahmed, Xiaoling Ou, Geoffrey R. Oxnard, Kiyotaka Yoh, Toyoaki Hida, Yuichiro Ohe, Hideo Saka, Manabu Hayama, Tomonori Hirashima, Ko Sugibayashi, Takayasu Kurata, Remy B. Verheijen
Publikováno v:
Targeted Oncology
Background Preliminary data suggest that combining savolitinib, a potent and highly selective MET-tyrosine kinase inhibitor (TKI), with osimertinib, a third-generation, irreversible, oral epidermal growth factor receptor-TKI (EGFR-TKI), may overcome
Autor:
Yasushi Okuno, Junichi Shimizu, Katsutoshi Seto, Shiro Fujita, Ryohei Katayama, Waki Hosoda, Yoshitsugu Horio, Toyoaki Hida, Mitsugu Araki, Katsuhiro Masago, Hiromi Furuta, Eiichi Sasaki, Yukari Sagae
Publikováno v:
Journal of Thoracic Oncology. 16:477-482
Objectives The purposes of this study are to clarify the details of the ALK tyrosine kinase inhibitor (TKI) resistance mechanism in rebiopsy cases and to predict novel resistance gene alterations using molecular dynamics simulation. Methods A total o
Autor:
Satoshi Nomura, Keisuke Aoe, Makoto Nishio, Toyoaki Hida, Takeshi Tajima, Kadoaki Ohashi, Takashi Seto, Masayuki Takeda, Sanae Moizumi, Shunichi Sugawara
Publikováno v:
Cancer Science
MET mutations leading to exon 14 skipping (METΔex14) are strong molecular drivers for non–small‐cell lung cancer (NSCLC). Capmatinib is a highly potent, selective oral MET inhibitor that showed clinically meaningful efficacy and a manageable saf
Autor:
Satoshi Tsukushi, Eiichi Sasaki, Yoshitsugu Horio, Shiro Fujita, Hiroaki Kuroda, Katsuhiro Masago, Toyoaki Hida
Publikováno v:
In Vivo
Background/aim The Archer FusionPlex platform is widely used for comprehensive fusion-gene detection in cancer tissues. This platform separately displays results for strong-evidence and weak-evidence fusion candidates (WEFCs). Distinctive fusion patt
Autor:
Mie Suzuki, Hidetoshi Hayashi, Makoto Nishio, Gerson Peltz, Takashi Nagasawa, Toyoaki Hida, Takashi Seto, Kei Fukuhara, Masayuki Ohkura, Miyako Satouchi, Yasushi Goto, Holger Thurm, Masahiro Morise, Naoyuki Nogami, Toshiaki Takahashi, Seiji Niho, Jun Sakakibara-Konishi
Publikováno v:
Cancer Science
Lorlatinib is a potent, brain‐penetrant, third‐generation anaplastic lymphoma kinase (ALK)/ROS proto‐oncogene 1 (ROS1) tyrosine kinase inhibitor (TKI) that is active against most known resistance mutations. This is an ongoing phase 1/2, multina
Autor:
Kazuhiro Asada, Joe Shindoh, Kazuyoshi Imaizumi, Masato Karayama, Akihito Kubo, Yuko Oya, Kenta Murotani, Eiji Kunii, Takafumi Suda, Sayako Morikawa, Tatsuya Yoshida, Toyoaki Hida, Takeshi Tsuda, Kentaro Ito, Kosuke Takahashi, Teppei Yamagichi, Tomoki Kimura, Shunsaku Hayai, Osamu Hataji, Hirokazu Taniguchi, Takashi Abe, Naoki Inui, Motoyasu Okuno
Publikováno v:
Cancer Science
We constructed a data set of EGFR‐mutant non–small‐cell lung carcinoma (NSCLC) patients, and compared the overall survival of first‐generation (1G), and second‐generation (2G) EGFR‐tyrosine kinase inhibitors (TKIs) in clinical practice us
Autor:
Toyoaki Hida, Teppei Yamaguchi
Publikováno v:
J Thorac Dis
JAMA Oncol
JAMA Oncol
IMPORTANCE: Consolidative programmed death ligand-1 (PD-L) inhibition after chemoradiotherapy improves overall survival and progression-free survival (PFS) for stage III non–small cell lung cancer (NSCLC) and requires safety evaluation for incorpor